News
Drug Pricing · Pharmaceuticals · Tariffs · Trade Policy
The U.S. government, under the Trump administration, announced the imposition of tariffs up to 100% on imported branded pharmaceuticals, targeting companies that do not commit to U.S. investment or "most favored nation" pricing agreements, a senior administration official stated.
This significant policy shift, unveiled by the White House, aims to incentivize domestic manufacturing and influence drug pricing. Nations or individual drugmakers can secure reduced levies by either striking specific deals with the Trump administration or by committing to build new manufacturing facilities within the United States.
The full 100% tariff specifically targets patented imported pharmaceuticals from companies that have not pledged investment in the U.S. and have not entered into "most favored nation" agreements. These agreements mandate that companies match their U.S. prices to the lowest prices they charge in other developed countries.
Despite the potential for such high tariffs, a senior administration official indicated that the maximum 100% tariff will ultimately apply to only a few companies.
